SRPT
Sarepta TherapeuticsANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-21
Current thesis
Bull case assumes positive program-specific safety/efficacy updates and clearer commercial traction for approved/skilled-access products, pushing multiples toward peer medians and supporting >80% upside vs. anchor.
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +9.9.
What can break
Clinical/safety setbacks in gene-therapy programs
Momentum
27
Value
52
Sentiment
100
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $24.00 · Bull $40.00 · Bear $12.00
Data freshness
Prices
As of 2026-07-21
Fundamentals
As of 2026-07-20 • Vendor: Data Vendor v1
Scores
As of 2026-07-21 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-12 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-07-21
Investment thesis
As of 2026-07-21
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $22.17
Why
Momentum27 · Δ7d -24.6
Value52 · Δ7d +0.3
Sentiment100 · Δ7d +9.9
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Sentiment · See AI snapshot
Momentum
27
26% active weight
Current posture
7d trendSoftening
Δ7d
-24.6
Δ21d
+16.9
Value
52
39% active weight
Current posture
7d trendFlat
Δ7d
+0.3
Δ21d
+0.3
Sentiment
100
34% active weight
Current posture
7d trendImproving
Δ7d
+9.9
Δ21d
-3.9
Why this grade
Composite grade A. Momentum 26.6 / Value 52.4 / Sentiment 100.0
Fundamentals (TTM)As of 2026-07-20
Fundamentals (TTM)
As of 2026-07-20
Market Cap
$1.78B
Beta
0.39
Shares Out
105.58M
P/E (TTM) · Derived
-2.4
P/S (TTM)
0.91
P/FCF (TTM) · Derived
14.66
Rev YoY
-1.9%
EPS YoY
-162.6%
Gross Margin
+60.6%
Op Margin
-11.0%
Net Debt
$99.9M
Current Ratio
4.63
As of 2026-07-21 • Updated nightlySource: Internal modelMethodology